This is quite possibly the most beautiful lipoprotein metabolism figure I have come across https://t.co/ziG1V6C60i pic.twitter.com/suSxd9qQpl
— Michael V Holmes (@mvholmes) April 15, 2016
How club drug ketamine fights #depressionhttps://t.co/5YGpQ9RJo6
— Andy Biotech (@AndyBiotech) May 5, 2016
metabolite via AMPARhttps://t.co/9MdcqbO7FU pic.twitter.com/ceJJbQrOju
Clinical success rates trending slightly upwards again https://t.co/0KqhB0dyMQ pic.twitter.com/c6V7ytAFPB
— Arsalan Arif (@AKAarsalan) May 23, 2016
A key discovery of a PD-L1 marker for (lack of) response to #cancer immunotherapy https://t.co/xNvIKYzLj6 @Nature pic.twitter.com/zxmcIUu5Bm
— Eric Topol (@EricTopol) May 23, 2016
Overcoming EGFR(T790M) and EGFR(C797S) resistance w/ mutant-selective allosteric inhibitorshttps://t.co/Dz4Pxy4bfZ pic.twitter.com/08rmWRG1pN
— Dan Marks (@Festivus159) May 25, 2016
A yeast model of cystic fibrosis reveals an evolutionarily conserved suppressor of the most common CF mutation ΔF508 https://t.co/hV6POvMJGE
— Perlstein Lab PBC (@PerlsteinLab) May 26, 2016
Regulatory T cells are promising targets for treating autoimmune and inflammatory diseases. https://t.co/DeK5XFZtSk pic.twitter.com/HMlrOfLFav
— NEJM (@NEJM) May 27, 2016
New McKinsey attrition study. NRDD https://t.co/1M4ftCQ3Of
— Bruce Booth (@LifeSciVC) May 27, 2016
Fig 3 confirms prior: in-licensed drugs succeed more: pic.twitter.com/cUs28nWtRA